Moore TJ - Search Results

1

Non-modulation as an intermediate phenotype in essential hypertension.

Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK. Williams GH, et al. Among authors: moore tj. Hypertension. 1992 Dec;20(6):788-96. doi: 10.1161/01.hyp.20.6.788. Hypertension. 1992. PMID: 1452294

2

Altered sodium perception in essential hypertensive patients following rapid volume expansion.

Conlin P, Moore T, Williams G, Hollenberg N. Conlin P, et al. J Hum Hypertens. 1999 Oct;13(10):701-6. doi: 10.1038/sj.jhh.1000852. J Hum Hypertens. 1999. PMID: 10516741

3

Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.

Swartz SL, Williams GH, Hollenberg NK, Moore TJ, Dluhy RG. Swartz SL, et al. Among authors: moore tj. Hypertension. 1979 Mar-Apr;1(2):106-11. doi: 10.1161/01.hyp.1.2.106. Hypertension. 1979. PMID: 233366

4

Dysregulation of aldosterone secretion and its relationship to the pathogenesis of essential hypertension.

Williams GH, Moore TJ, Hollenberg NK. Williams GH, et al. Among authors: moore tj. Endocrinol Metab Clin North Am. 1991 Jun;20(2):423-47. Endocrinol Metab Clin North Am. 1991. PMID: 1879402 Review.

5

Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans.

Cordero P, Fisher ND, Moore TJ, Gleason R, Williams GH, Hollenberg NK. Cordero P, et al. Among authors: moore tj. Hypertension. 1991 Apr;17(4):510-6. doi: 10.1161/01.hyp.17.4.510. Hypertension. 1991. PMID: 2013477

6

Angiotensin-mediated renin suppression is altered in non-modulating hypertension.

Seely EW, Moore TJ, Rogacz S, Gordon MS, Gleason RE, Hollenberg NK, Williams GH. Seely EW, et al. Among authors: moore tj. Hypertension. 1989 Jan;13(1):31-7. doi: 10.1161/01.hyp.13.1.31. Hypertension. 1989. PMID: 2642891

7

Changes in adrenal responsiveness and potassium balance with shifts in sodium intake.

Adler GK, Moore TJ, Hollenberg NK, Williams GH. Adler GK, et al. Among authors: moore tj. Endocr Res. 1987;13(4):419-45. doi: 10.3109/07435808709035467. Endocr Res. 1987. PMID: 3329091

8

Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension.

Crantz FR, Swartz SL, Hollenberg NK, Moore TJ, Dluhy RG, Williams GH. Crantz FR, et al. Among authors: moore tj. Hypertension. 1980 Sep-Oct;2(5):604-9. doi: 10.1161/01.hyp.2.5.604. Hypertension. 1980. PMID: 6158478 Clinical Trial.

9

Converting-enzyme inhibition corrects the altered adrenal response to angiotensin II in essential hypertension.

Taylor T, Moore TJ, Hollenberg NK, Williams GH. Taylor T, et al. Among authors: moore tj. Hypertension. 1984 Jan-Feb;6(1):92-9. doi: 10.1161/01.hyp.6.1.92. Hypertension. 1984. PMID: 6198274

10

Rapid modulation of renal and adrenal responsiveness to angiotensin II.

Conlin PR, Moore TJ, Williams GH, Hollenberg NK. Conlin PR, et al. Among authors: moore tj. Hypertension. 1993 Dec;22(6):832-8. doi: 10.1161/01.hyp.22.6.832. Hypertension. 1993. PMID: 7503952 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

238 results

Search Page

Filters